A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment

Alberti, Diego; Protti, Nicoletta; Toppino, Antonio; Deagostino, Annamaria; Lanzardo, Stefania; Bortolussi, Silva; Altieri, S.; Voena, Claudia; Chiarle, Roberto; Crich, Simonetta Geninatti; Aime, Silvio

doi:10.1016/j.nano.2014.12.004

Cited by 53 publications

(39 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intra-tumour and inter-patient tumour heterogeneity resulting in variable biodistribution and pharmacokinetics is a major problem in cancer treatments which rely on the targeted delivery of drugs to the malignancy, such as chemotherapy, therapeutic nuclear medicine and BNCT 84 – 88 . In clinical BNCT, theranostic approaches based on the use of radiolabelled or dual boron/gadolinium agents have been proposed to quantify the biodistribution of NCAs via positron emission tomography (PET) or magnetic resonance imaging (MRI) to improve the efficacy of neutron capture therapies 32 , 89 , 90 . 18 F-BPA, a radio-labelled analogue of 10 B-BPA has been successfully employed to determine the macrodistribution of boron in the tumour and estimate the tumour to normal tissue uptake ratio prior to treatment for treatment planning purposes 88 , 91 – 95 .…”

Section: Discussionmentioning

confidence: 99%

Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons

Safavi-Naeini

Chacon

Guatelli

et al. 2018

Sci Rep

View full text Add to dashboard Cite

This paper presents Neutron Capture Enhanced Particle Therapy (NCEPT), a method for enhancing the radiation dose delivered to a tumour relative to surrounding healthy tissues during proton and carbon ion therapy by capturing thermal neutrons produced inside the treatment volume during irradiation. NCEPT utilises extant and in-development boron-10 and gadolinium-157-based drugs from the related field of neutron capture therapy. Using Monte Carlo simulations, we demonstrate that a typical proton or carbon ion therapy treatment plan generates an approximately uniform thermal neutron field within the target volume, centred around the beam path. The tissue concentrations of neutron capture agents required to obtain an arbitrary 10% increase in biological effective dose are estimated for realistic treatment plans, and compared to concentrations previously reported in the literature. We conclude that the proposed method is theoretically feasible, and can provide a worthwhile improvement in the dose delivered to the tumour relative to healthy tissue with readily achievable concentrations of neutron capture enhancement drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons

Safavi-Naeini

Chacon

Guatelli

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These include agents active for fluorescence imaging and PDT,[45] agents that provide contrast for MRI and regress atherosclerosis via localized statin delivery,[44, 170] or provide contrast for MRI and treat tumors via BNCT. [212]…”

Section: Discussionmentioning

confidence: 99%

“…Subsequent developments include improved syntheses of the carborane lipids[211, 214] and success in use of carborane labeled LDL in conjunction with neutron irradiation to treat lung cancer. [212]…”

Section: Boron-neutron Capture Therapy With Ldlmentioning

confidence: 99%

Lipoproteins and lipoprotein mimetics for imaging and drug delivery

Thaxton

Rink

Naha

et al. 2016

Advanced Drug Delivery Reviews

121

View full text Add to dashboard Cite

Lipoproteins are a set of natural nanoparticles whose main role is the transport of fats within the body. While much work has been done to develop synthetic nanocarriers to deliver drugs or contrast media, natural nanoparticles such as lipoproteins represent appealing alternatives. Lipoproteins are biocompatible, biodegradable, non-immunogenic and are naturally targeted to some disease sites. Lipoproteins can be modified to act as contrast agents in many ways, such as by insertion of gold cores to provide contrast for computed tomography. They can be loaded with drugs, nucleic acids, photosensitizers or boron to act as therapeutics. Attachment of ligands can re-route lipoproteins to new targets. These attributes render lipoproteins attractive and versatile delivery vehicles. In this review we will provide background on lipoproteins, then survey their roles as contrast agents, in drug and nucleic acid delivery, as well as in photodynamic therapy and boron neutron capture therapy.

show abstract

“…With the exception of the foregoing proteins, several other proteins, e.g., silk fibroin (Bian et al, 2016 ; Khalid et al, 2016 ; Liu et al, 2016 ), zein (Wang et al, 2017b ), lipoprotein (Mathew et al, 2013 ; Alberti et al, 2015 ) and lactoferrin (Kamalapuram et al, 2016 ; Kanwar et al, 2016 ), have also been successfully employed for cancer theranostics, as detailed in Table 1 . For instance, multimodular zinc-doped Fe 3 O 4 -saturated bovine lactoferrin NPs (Zn-Fe-bLf NPs) were fabricated for a targeted theranostics application through oral administration (Kamalapuram et al, 2016 ).…”

Section: Othersmentioning

confidence: 99%

Bio-Inspired Protein-Based Nanoformulations for Cancer Theranostics

et al. 2018

View full text Add to dashboard Cite

Over the past decade, more interests have been aroused in engineering protein-based nanoformulations for cancer treatment. This excitement originates from the success of FDA approved Abraxane (Albumin-based paclitaxel nanoparticles) in 2005. The new generation of biocompatible endogenous protein-based nanoformulations is currently constructed through delivering cancer therapeutic and diagnostic agents simultaneously, as named potential theranostics. Protein nanoformulations are commonly incorporated with dyes, contrast agents, drug payloads or inorganic nanoclusters, serving as imaging-guided combinatorial cancer therapeutics. Employing the nature identity of proteins, the theranostics, escape the clearance by reticuloendothelial cells and have a long blood circulation time. The nanoscale sizet allows them to be penetrated deeply into tumor tissues. In addition, stimuli release and targeted molecules are incorporated to improve the delivery efficiency. The ongoing advancement of protein-based nanoformulations for cancer theranostics in recent 5 years is reviewed in this paper. Fine-designed nanoformulations based on albumin, ferritin, gelatin, and transferrin are highlighted from the literature. Finally, the current challenges are identified in translating protein-based nanoformulations from laboratory to clinical trials.

show abstract

A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment

Cited by 53 publications

References 36 publications

Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons

Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons

Lipoproteins and lipoprotein mimetics for imaging and drug delivery

Bio-Inspired Protein-Based Nanoformulations for Cancer Theranostics

Contact Info

Product

Resources

About